Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Cited by (1,066)

Items 101–200 of 1,066

1. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
   A. Murat, E. Migliavacca, T. Gorlia, W. L. Lambiv, T. Shay, M. Hamou, N. de Tribolet, L. Regli, W. Wick, M. Kouwenhoven et al. · 2008 · Journal of Clinical Oncology
2. Glioma targeted therapy: insight into future of molecular approaches
   Keyang Yang, Zhijing Wu, Hao Zhang, Nan Zhang, Wantao Wu, Zeyu Wang, Ziyu Dai, Xun Zhang, Liyang Zhang, Yun Peng et al. · 2022 · Molecular Cancer
3. Glioblastoma survival in the United States before and during the temozolomide era
   Derek Richard Johnson, Brian Patrick O’Neill · 2011 · Journal of Neuro-Oncology
4. Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
   Furtado, Denzil, Björnmalm, Mattias, Ayton, Scott, Bush, Ashley I., Kempe, Kristian, Caruso, Frank · 2018 · Advanced Materials
5. Radiation-induced brain injury: A review
   Dana M. Greene-Schloesser, Mike E. C. Robbins, Ann M. Peiffer, Edward G. Shaw, Kenneth T. Wheeler, Michael David Chan · 2012 · Frontiers in Oncology
6. Glioblastoma: pathology, molecular mechanisms and markers
   Aldape, Kenneth, Zadeh, Gelareh, Mansouri, Sheila, Reifenberger, Guido, von Deimling, Andreas · 2015 · Acta Neuropathologica
7. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model
   Alcantara Llaguno, Sheila, Chen, Jian, Kwon, Chang-Hyuk, Jackson, Erica L., Li, Yanjiao, Burns, Dennis K., Alvarez-Buylla, Arturo, Parada, Luis F. · 2009 · Cancer Cell
8. Molecular targeted therapy of glioblastoma
   Émilie Le Rhun, Matthias Preusser, Patrick Roth, David A. Reardon, Martin J. van den Bent, Patrick Yung Wen, Guido Reifenberger, Michael Weller · 2019 · Cancer Treatment Reviews
9. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials
   Benjamin M. Ellingson, Martin Bendszus, Jerrold L. Boxerman, Daniel P. Barboriak, Bradley James Erickson, Marion Smits, Sarah J. Nelson, Elizabeth Robins Gerstner, Brian Michael Alexander, Gregory Goldmacher et al. · 2015 · Neuro-Oncology
10. Survival in glioblastoma: a review on the impact of treatment modalities
    Pedro David Delgado López, Eva María Corrales-García · 2016 · Clinical & Translational Oncology
11. Mechanisms and therapeutic implications of hypermutation in gliomas
    Mehdi Touat, Yvonne Y. Li, Adam N. Boynton, Liam Flinn Spurr, Julian Bryan Iorgulescu, Craig L. Bohrson, Isidro Cortés‐Ciriano, Cristina Birzu, Jack E. Geduldig, Kristine Pelton et al. · 2020 · Nature
12. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
    Daniela F. Quail, Robert L. Bowman, Leila Akkari, Marsha L. Quick, Alberto J. Schuhmacher, Jason T. Huse, Eric C. Holland, James C. Sutton, Johanna A. Joyce · 2016 · Science
13. Advances in the molecular genetics of gliomas — implications for classification and therapy
    Reifenberger, Guido, Wirsching, Hans-Georg, Knobbe-Thomsen, Christiane B., Weller, Michael · 2017 · Nature Reviews Clinical Oncology
14. Epidemiology of Glioblastoma Multiforme–Literature Review
    Szymon Grochans, Anna Maria Cybulska, Donata Simińska, Jan Korbecki, Klaudyna Kojder, Dariusz Chlubek, Irena Baranowska‐Bosiacka · 2022 · Cancers
15. Proteogenomic and metabolomic characterization of human glioblastoma
    Wang, Liang-Bo, Karpova, Alla, Gritsenko, Marina A., Kyle, Jennifer E., Cao, Song, Li, Yize, Rykunov, Dmitry, Colaprico, Antonio, Rothstein, Joseph H., Hong, Runyu et al. · 2021 · Cancer Cell
16. Notch Promotes Radioresistance of Glioma Stem Cells
    Jialiang Wang, Timothy P. Wakeman, Justin Durla Lathia, Anita B. Hjelmeland, Xiao-Fan Wang, Rebekah Ruth White, Jeremy N. Rich, Bruce A. Sullenger · 2009 · Stem Cells
17. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
    Anoop P. Patel, James L. Fisher, Emma L. Nichols, Foad Abd-Allah, Jemal Abdela, Ahmed Abdelalim, Haftom Niguse Abraha, Dominic Agius, Fares Alahdab, Shazia Alam et al. · 2019 · The Lancet Neurology
18. Integrin Alpha 6 Regulates Glioblastoma Stem Cells
    Justin Durla Lathia, Joseph Gallagher, John M. Heddleston, Jialiang Wang, Christine Elissa Eyler, Jennifer MacSwords, Qiulian Wu, Amit Vasanji, Roger E. McLendon, Anita B. Hjelmeland et al. · 2010 · Cell stem cell
19. Metronomic chemotherapy: new rationale for new directions
    Eddy Pasquier, Maria Kavallaris, Nicolás André · 2010 · Nature Reviews Clinical Oncology
20. FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme
    Martin H. Cohen, Yuan Li Shen, Patricia Keegan, Richard Pazdur · 2009 · The Oncologist
21. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
22. NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma Cells and Inhibits Growth of Tumor Neurospheres and Xenografts
    Xing Fan, Leila Khaki, Thant S. Zhu, Mary E. Soules, Caroline E. Talsma, Naheed Gul, Cheryl M. Koh, Jiangyang Zhang, Yue‐Ming Li, Jarek Maciaczyk et al. · 2009 · Stem Cells
23. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
    Suzie J. Scales, Frédéric J. de Sauvage · 2009 · Trends in Pharmacological Sciences
24. Glioma
    Michael Weller, Patrick Yung Wen, Susan Marina Chang, Linda Dirven, Michael K. Lim, Michelle Monje, Guido Reifenberger · 2024 · Nature Reviews Disease Primers
25. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
    Kurt Alex Schalper, Maria Esperanza Rodriguez-Ruiz, Ricardo Díez-Valle, Álvaro López‐Janeiro, Angelo Porciuncula, Miguel Angel Idoate, Susana Inogés, Carlos de Andrea, Ascensión López-Dı́az de Cerio, Sonia Tejada et al. · 2019 · Nature Medicine
26. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas
    Martin J. van den Bent, JS Wefel, David Schiff, MARTIN J.B. TAPHOORN, Kurt A. Jaeckle, Larry Junck, Terri S. Armstrong, Ali K. Choucair, Adam D. Waldman, Thierry Gorlia et al. · 2011 · The Lancet Oncology
27. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells
    Chang, Alan L., Miska, Jason, Wainwright, Derek A., Dey, Mahua, Rivetta, Claudia V., Yu, Dou, Kanojia, Deepak, Pituch, Katarzyna C., Qiao, Jian, Pytel, Peter et al. · 2016 · Cancer Research
28. An anatomic transcriptional atlas of human glioblastoma
    Ralph B. Puchalski, Nameeta Shah, Jeremy A. Miller, Rachel A. Dalley, Steve R. Nomura, Jae-Guen Yoon, Kimberly A. Smith, Michael Lankerovich, Darren Bertagnolli, Kris Bickley et al. · 2018 · Science
29. Diffuse brainstem glioma in children: critical review of clinical trials
    Darren R. Hargrave, Ute Katharina Bartels, Éric Bouffet · 2006 · The Lancet Oncology
30. Diffuse glioma growth: a guerilla war
    An Claes, Albert J. S. Idema, Pieter Wesseling · 2007 · Acta Neuropathologica
31. Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study
    Todd G. Mainprize, Nir Lipsman, Yuexi Huang, Ying Meng, Allison J. Bethune, Sarah Ironside, Chris Heyn, Ryan D. Alkins, Maureen Trudeau, Arjun Sahgal et al. · 2019 · Scientific Reports
32. Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
    Michael Weller, Jörg Felsberg, Christian Johannes Hartmann, Hilmar Berger, Joachim Peter Steinbach, Johannes Schramm, Manfred Westphal, Gabriele Schackert, Matthias Simon, Jörg Christian Tonn et al. · 2009 · Journal of Clinical Oncology
33. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
    Ricklefs, Franz L., Alayo, Quazim, Krenzlin, Harald, Mahmoud, Ahmad B., Speranza, Maria C., Nakashima, Hiroshi, Hayes, Josie L., Lee, Kyungheon, Balaj, Leonora, Passaro, Carmela et al. · 2018 · Science Advances
34. Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
    Tracy T. Batchelor, Paul James Mulholland, Bart Neyns, Burt Nabors, Mario Campone, Antje Wick, Warren P. Mason, Tom Mikkelsen, Surasak Phuphanich, Lynn Stuart Ashby et al. · 2013 · Journal of Clinical Oncology
35. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014
    Quinn T. Ostrom, David J. Coté, Mustafa Steven Ascha, Carol A. Kruchko, Jill S. Barnholtz‐Sloan · 2018 · JAMA Oncology
36. CGCG clinical practice guidelines for the management of adult diffuse gliomas
    Tao Jiang, Ying Qing Mao, Wenbin Ma, Qing Mao, Yongping You, Xuejun Yang, Chuanlu Jiang, Chunsheng Kang, Xuejun Li, Ling Chen et al. · 2016 · Cancer Letters
37. Therapy with oncolytic viruses: progress and challenges
    Sophia Z. Shalhout, David Michael Miller, Kevin S. Emerick, Howard L. Kaufman · 2023 · Nature Reviews Clinical Oncology
38. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
    Nicholas Arthur Butowski, Howard Colman, John de Groot, Antonio M. P. Omuro, Lakshmi Nayak, Patrick Yung Wen, Timothy Francis Cloughesy, Adhirai Marimuthu, Sam Haidar, Arie Perry et al. · 2015 · Neuro-Oncology
39. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma
    Toshiro Hara, Rony Chanoch-Myers, Nathan D. Mathewson, Chad Myskiw, Lyla Atta, Lillian Bussema, Stephen W. Eichhorn, Alissa Greenwald, Gabriela Sarti Kinker, Christopher Rodman et al. · 2021 · Cancer Cell
40. Current and future strategies for treatment of glioma
    Nancy Ann Oberheim Bush, Susan Marina Chang, Mitchel Stuart Berger · 2016 · Neurosurgical Review
41. Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications
    Jaber Beik, Ziaeddin Abed, Fatemeh S. Ghoreishi, Samira Hosseini-Nami, Saeed Mehrzadi, Ali Shakeri‐Zadeh, Seyed Kamran Kamrava · 2016 · Journal of Controlled Release
42. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
    Kaitlin Graham, Evan C. Unger · 2018 · International Journal of Nanomedicine
43. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial
    Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe S. Schlegel, Michael Sabel, Peter Hau, Rolf‐Dieter Kortmann, Dietmar Krex, Oliver Martin Grauer et al. · 2019 · The Lancet
44. Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
    Stuart A. Grossman, Xiaobu Ye, Glenn Jay Lesser, Andrew Edward Sloan, Hetty E. Carraway, Serena Desideri, Steven Piantadosi · 2011 · Clinical Cancer Research
45. Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
    Martin J. van den Bent, Alba Ariela Brandes, R. Rampling, Mathilde C.M. Kouwenhoven, Johan M. Kros, Antoine F. Carpentier, Paul M. Clément, Marc Frénay, Mario Campone, Jean‐François Baurain et al. · 2009 · Journal of Clinical Oncology
46. TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human Glioblastoma
    Judit Anido, Andrea Sáez‐Borderías, Alba Gonzàlez-Juncà, Laura Rodón, Gerard Folch, Marı́a A. Carmona, Rosa M. Prieto-Sánchez, Ignasi Barba, Elena A. Martínez-Sáez, Ludmila Prudkin et al. · 2010 · Cancer Cell
47. Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
    Derek A. Wainwright, Alan Lee Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex L. Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang et al. · 2014 · Clinical Cancer Research
48. ‘Pseudopalisading’ Necrosis in Glioblastoma: A Familiar Morphologic Feature That Links Vascular Pathology, Hypoxia, and Angiogenesis
    Yuan Rong, Donald L. Durden, Erwin G. Van Meir, Daniel Jay Brat · 2006 · Journal of Neuropathology & Experimental Neurology
49. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy
    Charles Couturier, Shamini Ayyadhury, Phuong Uyen Le, Javad Nadaf, Jean Monlong, Gabriele Riva, Redouane Allache, Salma Baig, Xiaohua Yan, Mathieu Bourgey et al. · 2020 · Nature Communications
50. Emerging insights into the molecular and cellular basis of glioblastoma
    Gavin P. Dunn, Mikael L. Rinne, Jill Wykosky, Giannicola Genovese, Steven N. Quayle, Ian F. Dunn, Pankaj Kumar Agarwalla, Milan G. Chheda, Benito Campos, Alan Wang et al. · 2012 · Genes & Development
51. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia, Martin J. van den Bent, Monika E. Hegi, R.O. Mirimanoff, Michael Weller, John Gregory Cairncross, Elizabeth A. Eisenhauer, Karl Bélanger, Alba Ariela Brandes, Anouk Allgeier et al. · 2007 · The Lancet Oncology
52. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
    Sturm, Dominik, Bender, Sebastian, Jones, David T. W., Lichter, Peter, Grill, Jacques, Becher, Oren, Hawkins, Cynthia, Majewski, Jacek, Jones, Chris, Costello, Joseph F. et al. · 2014 · Nature Reviews Cancer
53. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
    Luiz Celso Hygino da Cruz, Isabel Rodríguez, R. C. Domingues, Emerson L. Gasparetto, Alma Gregory Sorensen · 2011 · American Journal of Neuroradiology
54. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
    Michael K. Lim, Michael Weller, Ahmed Idbaïh, Joachim Peter Steinbach, Gaetano Finocchiaro, Raju R. Raval, George Ansstas, Joachim M. Baehring, Jennie Webster Taylor, Jérôme Honnorat et al. · 2022 · Neuro-Oncology
55. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Xiaoman Li, Changjing Wu, Nianci Chen, Huadi Gu, Allen Yen, Liu Cao, Enhua Wang, Liang Wang · 2016 · Oncotarget
56. Glioblastoma multiforme: a review of where we have been and where we are going
    Cory Adamson, Okezie Obasi Kanu, Ankit Indravadan Mehta, Chunhui Di, Ningjing Lin, Austin K. Mattox, Darell D. Bigner · 2009 · Expert Opinion on Investigational Drugs
57. The integrated landscape of driver genomic alterations in glioblastoma
    Veroniquè Frattini, Vladimir Trifonov, Joseph Minhow Chan, Angelica M. Castano, Marie Lia, Francesco Abate, Stephen Thomas Keir, Alan X. Ji, Pietro Zoppoli, Francesco Niola et al. · 2013 · Nature Genetics
58. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound
    Lisa Hsu Treat, Nathan Judson McDannold, Natalia I. Vykhodtseva, Yongzhi Zhang, Karen Tam, Kullervo Hynynen · 2007 · International Journal of Cancer
59. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
    Burt Nabors, Jana Portnow, Manmeet Singh Ahluwalia, Joachim M. Baehring, Henry Brem, Steven S. Brem, Nicholas Arthur Butowski, Jian Li Campian, Stephen W. Clark, Andrew J. Fabiano et al. · 2020 · Journal of the National Comprehensive Cancer Network
60. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
    Linda M. Liau, Keyoumars Ashkan, David Dinh Tran, Jian Li Campian, John E. Trusheim, Charles Cobbs, Jason Heth, Michael E. Salacz, Sarah A. Taylor, Stacy D. D’Andre et al. · 2018 · Journal of Translational Medicine
61. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
    Ryan C. Gimple, Shruti Bhargava, Deobrat Dixit, Jeremy N. Rich · 2019 · Genes & Development
62. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas
    McGirt, Matthew J., Chaichana, Kaisorn L., Attenello, Frank J., Weingart, Jon D., Than, Khoi, Burger, Peter C., Olivi, Alessandro, Brem, Henry, Quinoñes-Hinojosa, Alfredo · 2008 · Neurosurgery
63. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
    Rolf F. Barth, MGraca H Vicente, O. K. Harling, W. S. Kiger, K. J. Riley, Peter J. Binns, F.M. Wagner, Minoru Suzuki, Teruhito Aihara, Itsuro Kato et al. · 2012 · Radiation Oncology
64. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
    Antonio M. P. Omuro, Alba Ariela Brandes, Antoine F Carpentier, Ahmed Idbaïh, David A. Reardon, Timothy Francis Cloughesy, Ashley Love Sumrall, Joachim M. Baehring, Martin J. van den Bent, Oliver Bähr et al. · 2022 · Neuro-Oncology
65. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
    Duane A. Mitchell, Kristen A. Batich, Michael Dee Gunn, Min-Nung Huang, Luis A Sanchez-Perez, Smita K. Nair, Kendra L. Congdon, Elizabeth A. Reap, Gary E. Archer, Annick Desjardins et al. · 2015 · Nature
66. Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
    Roger Stupp, Monika E. Hegi, Mark R. Gilbert, Arnab Chakravarti · 2007 · Journal of Clinical Oncology
67. Epidemiology and Outcome of Glioblastoma
    Ahmad Tamimi, Malik Eid Juweid · 2017 · Codon Publications eBooks
68. Glioblastoma: defining tumor niches
    Hambardzumyan, Dolores, Bergers, Gabriele · 2015 · Trends in Cancer
69. Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
    Wolfgang Wick, Vinay K. Puduvalli, Marc Charles Chamberlain, Martin J. van den Bent, Antoine F. Carpentier, Lawrence Cher, Warren P. Mason, Michael Weller, Shengyan Hong, Luna C. Musib et al. · 2010 · Journal of Clinical Oncology
70. Applications of focused ultrasound in the brain: from thermoablation to drug delivery
    Ying Meng, Kullervo Hynynen, Nir Lipsman · 2020 · Nature Reviews Neurology
71. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
    Myrna R. Rosenfeld, Xiaobu Ye, Jeffrey G. Supko, Serena Desideri, Stuart A. Grossman, Steven S. Brem, Tom Mikkelson, Daniel Y. Wang, Yunyoung Claire Chang, Janice Hu et al. · 2014 · Autophagy
72. Glioblastoma: From Molecular Pathology to Targeted Treatment
    Timothy Francis Cloughesy, Webster K. Cavenee, Paul S. Mischel · 2011 · Annual Review of Pathology Mechanisms of Disease
73. Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme
    Julio Sotelo, Eduardo Briceño, Miguel Angel López-González · 2006 · Annals of Internal Medicine
74. Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
    R.O. Mirimanoff, Thierry Gorlia, Warren P. Mason, Martin J. van den Bent, Rolf‐Dieter Kortmann, Barbara Fisher, Michele Reni, Alba Ariela Brandes, Juergen Curschmann, S. Villà et al. · 2006 · Journal of Clinical Oncology
75. Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
    Matthew H. Kulke, Keith E. Stuart, Peter C. Enzinger, David P. Ryan, Jeffrey William Clark, Alona Muzikansky, Michele Vincitore, Ann L. Michelini, Charles S. Fuchs · 2006 · Journal of Clinical Oncology
76. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
    John de Groot, Gregory N. Fuller, Ashok J. Kumar, Y. Piao, Karina Agda Eterovic, Y. Ji, Charles A. Conrad · 2010 · Neuro-Oncology
77. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma
    Kaisorn Lee Chaichana, Ignacio Jusué-Torres, Rodrigo Navarro-Ramírez, Shaan Mohammed Raza, María Pascual-Gallego, Aly Ibrahim, Marta Hernandez-Hermann, Luis Gomez, Xiaobu Ye, JON D. WEINGART et al. · 2013 · Neuro-Oncology
78. Modeling Patient-Derived Glioblastoma with Cerebral Organoids
    Linkous, Amanda, Balamatsias, Demosthenes, Snuderl, Matija, Edwards, Lincoln, Miyaguchi, Ken, Milner, Teresa, Reich, Batsheva, Cohen-Gould, Leona, Storaska, Andrew, Nakayama, Yasumi et al. · 2019 · Cell Reports
79. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine
    Wynand Paul Roos, Luís F.Z. Batista, Steffen C. Naumann, Wolfgang Wick, Michael Weller, Carlos Frederico Martins Menck, Bernd Kaina · 2006 · Oncogene
80. Glioma progression is shaped by genetic evolution and microenvironment interactions
    Frederick S. Varn, Kevin C. Johnson, Jan Martinek, Jason T. Huse, MacLean P. Nasrallah, Pieter Wesseling, Lee Cooper, Tathiane Maistro Malta, Taylor E. Wade, Thaís S. Sabedot et al. · 2022 · Cell
81. Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy
    Jeremy Ruben, Michael J. Dally, Michael Bailey, Robin Smith, Catriona McLean, Pasqual Fedele · 2006 · International Journal of Radiation Oncology*Biology*Physics
82. Glioblastoma
    Hans‐Georg Wirsching, Evanthia Galanis, Michael Weller · 2016 · Handbook of clinical neurology
83. Improved survival time trends for glioblastoma using the SEER 17 population-based registries
    Matthew Koshy, John Lee Villano, Therese A. Dolecek, Andrew R. Howard, Usama X. Mahmood, Steven J. Chmura, Ralph R. Weichselbaum, Bridget J. McCarthy · 2011 · Journal of Neuro-Oncology
84. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
    Benjamin M. Ellingson, Patrick Yung Wen, Timothy Francis Cloughesy · 2017 · Neurotherapeutics
85. Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
    David A. Reardon, Karen Fink, Tom Mikkelsen, Timothy Francis Cloughesy, A. O’Neill, Scott Randall Plotkin, Michael Glantz, Paula D. Ravin, Jeffrey J. Raizer, Keith M. Rich et al. · 2008 · Journal of Clinical Oncology
86. DNA Methylation Cancer Biomarkers: Translation to the Clinic
    Warwick J. Locke, Dominic Guanzon, Chenkai Ma, Yi Jin Liew, Konsta Duesing, Kim Y. C. Fung, Jason P. Ross · 2019 · Frontiers in Genetics
87. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
    Linda M. Liau, Keyoumars Ashkan, Steven S. Brem, Jian Li Campian, John E. Trusheim, FABIO MASSAITI IWAMOTO, David Dinh Tran, George Ansstas, Charles Cobbs, Jason Heth et al. · 2022 · JAMA Oncology
88. IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
    Derek Alan Wainwright, Irina V. Balyasnikova, Alan Lee Chang, Atique U. Ahmed, Kyung‐Sub Moon, Brenda Auffinger, Alex L. Tobias, Yu Han, Maciej S. Lesniak · 2012 · Clinical Cancer Research
89. EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance
    Mario-Luca Suvà, Nicolò Riggi, Michalina Janiszewska, Ivan Radovanovic, Paolo Provero, Jean‐Christophe Stehle, Karine Baumer, Marie‐Aude Le Bitoux, Denis Marino, Luisa Cironi et al. · 2009 · Cancer Research
90. Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
    Walter Taal, Dieta Brandsma, Hein G. de Bruin, Jacoline E. C. Bromberg, Annemarie T. Swaak‐Kragten, Peter A.E. Sillevis Smitt, Corine A. van Es, Martin J. van den Bent · 2008 · Cancer
91. Current Clinical Brain Tumor Imaging
    Javier E. Villanueva-Meyer, Marc C. Mabray, Soonmee Cha · 2017 · Neurosurgery
92. A highlight on Sonic hedgehog pathway
    Carballo, Gabriela Basile, Honorato, Jéssica Ribeiro, de Lopes, Giselle Pinto Farias, Spohr, Tania Cristina Leite de Sampaio e · 2018 · Cell Communication and Signaling
93. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma
    Jordan, Andreas, Scholz, Regina, Maier-Hauff, Klaus, van Landeghem, Frank K.H., Waldoefner, Norbert, Teichgraeber, Ulf, Pinkernelle, Jens, Bruhn, Harald, Neumann, Fabian, Thiesen, Burghard et al. · 2006 · Journal of Neuro-Oncology
94. Diffuse Glioma Heterogeneity and Its Therapeutic Implications
    James Nicholson, Howard Alan Fine · 2021 · Cancer Discovery
95. Gliomas Promote Immunosuppression through Induction of B7-H1 Expression in Tumor-Associated Macrophages
    Orin G. Bloch, Courtney A. Crane, Rajwant Kaur, Michael Safaee, Martin J. Rutkowski, Andrew T. Parsa · 2013 · Clinical Cancer Research
96. Current concepts and management of glioblastoma
    Matthias Preusser, Sandrine de Ribaupierre, Adelheid Wöehrer, Sara Erridge, Monika E. Hegi, Michael Weller, Roger Stupp · 2011 · Annals of Neurology
97. Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
    Albert Lai, Anh Nhat Tran, Phioanh Leia Nghiemphu, Whitney B. Pope, Orestes E. Solis, Michael T. Selch, Emese Filka, William H. Yong, Paul S. Mischel, Linda M. Liau et al. · 2010 · Journal of Clinical Oncology
98. Recent advances in the molecular understanding of glioblastoma
    Fonnet E. Bleeker, Remco Jurriaan Molenaar, Sieger Leenstra · 2012 · Journal of Neuro-Oncology
99. Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
    Roger Stupp, Monika E. Hegi, Bart Neyns, Roland Goldbrunner, Uwe S. Schlegel, Paul M. Clément, Gerhard G. Grabenbauer, Adrian F. Ochsenbein, Matthias Simon, Pierre-Yves Dietrich et al. · 2010 · Journal of Clinical Oncology
100. An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
     Guo, Deliang, Reinitz, Felicia, Youssef, Mary, Hong, Cynthia, Nathanson, David, Akhavan, David, Kuga, Daisuke, Amzajerdi, Ali Nael, Soto, Horacio, Zhu, Shaojun et al. · 2011 · Cancer Discovery